Bone Marrow Transplantation: Comprehensive Clinical Approach

Primary Indications

Allogeneic hematopoietic cell transplantation (alloHCT) is indicated for intermediate or adverse risk acute myeloid leukemia (AML) in first complete remission (CR1) for patients aged ≤75 years, with donor availability and patient fitness being key considerations. 1

Disease-Specific Indications

Acute Myeloid Leukemia:

Intermediate or adverse risk AML in CR1 (age ≤75 years) 1
BCR-ABL-positive patients should undergo alloHCT immediately upon achieving remission 1
Comorbidities must be carefully evaluated using HCT-CI (Hematopoietic Cell Transplantation Comorbidity Index), which predicts non-relapse mortality and overall survival 1

Myelodysplastic Syndromes (MDS):

IPSS intermediate-2 and high-risk patients aged ≤60 years should be transplanted soon after diagnosis for longest life expectancy 2
IPSS low-risk patients benefit from delaying HCT until disease progression 2
IPSS intermediate-1 risk requires individualized decisions based on platelet/neutrophil counts 2
Lower-risk patients (WPSS) achieve 80% 5-year overall survival following alloHCT 2

Severe Aplastic Anemia (SAA):

Upfront HSCT for children and young adults with matched related donors 3
Refractory/relapsed SAA patients <50 years who fail immunosuppressive therapy 4
SAA patients 50-60 years with ECOG ≤2 who fail IST 4

Other Hematologic Conditions:

Chronic lymphocytic leukemia with high-risk cytogenetics or refractory to purine analogs 4
Transfusion-dependent severe thalassemia (recommended before stage 3 progression in children 2-6 years) 4
Fanconi anemia (before progression to MDS or leukemia) 4

Donor Selection Algorithm

First priority is HLA-identical donor (sibling or unrelated donor with 10/10 or 9/10 HLA match if search time <3 months from diagnosis), with second and third priority being umbilical cord blood or haploidentical donor based on center experience and patient age. 1

Donor Hierarchy:

HLA-matched sibling donor (MSD) - preferred choice 4
HLA-matched unrelated donor (8/8 match) - if available within 8 weeks 4
Haploidentical donor - if urgent transplantation needed or no matched donor available 1, 4
Umbilical cord blood - alternative when no matched donor available 1

Haploidentical Donor Selection (when multiple candidates available):

For AML patients ≥40 years: prefer young donors 1
For patients <40 years: donor age and kinship have no impact on outcome 1
Father donors associated with lower non-relapse mortality and acute GVHD compared to mother donors 4
Child donors have lower acute GVHD than sibling donors 4

Important caveat: HLA-matched unrelated donor results now comparable to HLA-matched siblings 2, making transplantation viable for nearly all patients 1.

Conditioning Regimens

Myeloablative conditioning (MAC) is recommended for patients aged ≤55 years with HCT-CI <2, while reduced-intensity conditioning (RIC) is recommended for all other patients. 1

Myeloablative Conditioning (MAC):

For AML/MDS (age ≤55 years, HCT-CI <2):

Fludarabine/Busulfan (Flu/Bu4) - associated with less toxicity than Bu/Cy in younger fit patients 1
Busulfan/Cyclophosphamide (Bu/Cy) - widely utilized alternative 1
Cyclophosphamide/TBI (Cy/TBI) - no convincing superiority over Bu/Cy or Flu/Bu4 1
TBI-based regimens - specifically indicated for CNS disease at presentation or myeloid sarcoma 1

For Severe Aplastic Anemia:

Fludarabine/Cyclophosphamide/ATG (Flu/Cy/ATG) or Cyclophosphamide/ATG (Cy/ATG) - optimal regimens for HLA-matched sibling BMT with 91% 5-year survival 5
Bone marrow graft source preferred over peripheral blood with ATG-based conditioning 3
Rabbit-derived ATG preferred over equine-derived ATG (lower grade II-IV acute GVHD risk) 5

Reduced-Intensity Conditioning (RIC):

Indications:

Patients >55 years regardless of comorbidities 1, 4
Patients with HCT-CI ≥3 regardless of age 4
Patients with poor organ function 4

Common RIC regimens:

Fludarabine-containing regimens 4
ATG-included RIC regimens 4
For MDS: patients >55-65 years, especially with >10% marrow myeloblasts 2

Critical consideration: RIC regimens rely more on graft-versus-leukemia (GvL) effect and require careful immunosuppression management and potential cell therapy to reduce relapse risk 4.

Intensified Regimens:

Reserved for young patients with refractory/relapsed disease:

Addition of Ara-C, VP16, Melphalan, TBI, Fludarabine, or Tespamin to standard conditioning 4
May reduce relapse incidence but increase transplant-related mortality without significantly improving overall survival 4

Graft-Versus-Host Disease (GVHD) Prophylaxis

GVHD prophylaxis is a critical component of alloHCT, and standardized prophylaxis following EBMT-ELN working group recommendations should be implemented. 1

Standard Prophylaxis Approaches:

For ATG-based conditioning:

Cyclosporine + Methotrexate - preferred for bone marrow grafts 3
Bone marrow graft source preferred when using ATG-based regimens 3

For Alemtuzumab-based conditioning:

Cyclosporine alone - acceptable with either bone marrow or peripheral blood stem cells 3

For Haploidentical Transplant:

Post-transplant cyclophosphamide - marked reduction in graft failure and GVHD 3, 6
Haploidentical transplants show similar leukemia-free survival and overall survival when using post-transplant cyclophosphamide 1

For Cord Blood Transplant:

Cyclosporine + Methylprednisolone 4

Supportive Care and Post-Transplant Management

Maintenance Treatment:

Post-alloHCT maintenance remains controversial and is generally not recommended outside clinical trials. 1

Key considerations:

Midostaurin maintenance approved only after chemotherapy consolidation, NOT after alloHCT 1
Midostaurin maintenance should not replace alloHCT in transplant candidates 1
Sorafenib maintenance for FLT3-ITD-positive AML after alloHCT requires larger randomized trial results before recommendation 1
Prophylactic hypomethylating agent (HMA) treatment after alloHCT may increase toxicity without benefit in patients curable with alloHCT alone 1

Graft Source Considerations:

Peripheral blood progenitor cells (PBPCs):

Easier collection, faster engraftment, reduced graft failure risk 7
Caveat: Increased GVHD risk compared to bone marrow grafts 7

Bone marrow grafts:

Lower GVHD risk 7
Indicated for severe aplastic anemia and nonmalignant disorders 7
Advocated for haploidentical HCT 7

Umbilical cord blood:

Rapid procurement, lower GVHD incidence, less-stringent HLA matching 7
Limitations: Cell dose constraints in high body weight recipients, delayed engraftment, higher graft failure risk, higher infectious complications 7
More favorable outcomes in pediatric populations 7

Age-Related Outcomes:

Survival is significantly lower in patients >30 years after both HLA-matched sibling (HR 2.74) and unrelated donor (HR 1.98) transplantation, independent of conditioning regimen. 5

Common Pitfalls and Caveats

Critical timing consideration: Patients need transplantation in due time; HLA-identical donor search should not exceed 3 months from diagnosis 1

Comorbidity assessment is mandatory: HCT-CI combined with EBMT score predicts non-relapse mortality for RIC alloHCT in CR1 1

Disease status matters: Pre-HCT debulking therapy often given for high blast counts before RIC 2

Evidence quality concern: Only 6% of standard-of-care recommendations for allogeneic transplantation are supported by randomized controlled trials, with widespread adoption based on historical precedent and observational data 8

Age should not be sole exclusionary factor: Studies support transplantation in patients 60-75 years using nonmyeloablative conditioning, with comorbidities and disease status being more relevant than age alone 2

What are the indications for bone marrow transplantation and the recommended transplant type, conditioning regimen, graft‑versus‑host disease prophylaxis, and supportive care?

Have a follow-up question?